Certara Inc (CERT)

Currency in USD
4.59
+0.03(+0.66%)
Closed·
4.75+0.16(+3.49%)
·
CERT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.544.70
52 wk Range
4.4513.88
Key Statistics
Prev. Close
4.56
Open
4.61
Day's Range
4.54-4.7
52 wk Range
4.45-13.88
Volume
2.9M
Average Volume (3m)
3.83M
1-Year Change
-61.0357%
Book Value / Share
6.39
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CERT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.62
Upside
+65.97%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Certara Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Neutral
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
7 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.62
(+65.97% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Hold10.00+117.86%11.00MaintainMay 12, 2026
BMO Capital
Hold6.00+30.72%7.00MaintainMay 12, 2026
Stephens
Buy9.00+96.08%10.00MaintainMay 12, 2026
Baird
Hold6.00+30.72%7.00MaintainMay 12, 2026
Barclays
Hold6.50+41.61%8.00MaintainMay 12, 2026

Certara Inc SWOT Analysis


Biosim Breakthrough
Certara leads in biosimulation software, with Q2 revenue of $104.6M, up 12% YoY. Strong financials and market position drive growth in drug development tech.
Animal Testing Pivot
Explore Certara's push into animal testing alternatives, targeting a multi-billion dollar market. This aligns with FDA's move to phase out animal testing.
Valuation Insights
Analysts set an average price target of $14, reflecting Certara's premium valuation. The company trades at 15x estimated 2025 EBITDA, above some peers.
Future-Proofing Strategy
Learn about CertaraIQ, launching Q4 2025, and how it could boost the company's competitive edge in the evolving biosimulation landscape.
Read full SWOT analysis

Certara Inc Earnings Call Summary for Q1/2026

  • Q1 2026 EPS of $0.09 missed forecast of $0.11 by 18%; revenue of $106.9M slightly beat expectations, up 1% YoY
  • Stock plunged 19.33% to $5.09 post-announcement; down 59% over past year, trading near 52-week low of $4.78
  • Software segment grew 7% YoY to $49.7M driven by Simcyp and Phoenix; services revenue declined 4% YoY to $57.2M
  • Company forecasts EPS improvement to $0.11 in Q2 2026 and $0.12 in Q3 2026; analyst price targets range $6-$10
  • CEO cited profitability challenges; focusing on AI-integrated platform development and cost rationalization to enhance margins
Last Updated: 14/05/2026, 13:32
Read Full Transcript

Earnings

Latest Release
May 11, 2026
EPS / Forecast
0.09 / 0.11
Revenue / Forecast
106.9M / 106.1M
EPS Revisions
Last 90 days

CERT Income Statement

Compare CERT to Peers and Sector

Metrics to compare
CERT
Peers
Sector
Relationship
P/E Ratio
−47.3x−0.4x−0.5x
PEG Ratio
0.12−0.020.00
Price/Book
0.7x1.4x2.6x
Price / LTM Sales
1.7x1.4x3.2x
Upside (Analyst Target)
71.7%37.8%55.3%
Fair Value Upside
Unlock38.9%9.7%Unlock

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Employees
1546

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
68.41M43.98%311.97M
Other Institutional Investors
122.99M56.02%560.83M
Public Companies & Retail Investors
0.000.00%0.00
Total
191.4M100.00%872.8M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Arsenal Capital Management LP23.36%36,345,835165,737
BlackRock, Inc.8.95%13,926,86363,506

People Also Watch

50.88
CTSH
-1.00%
455.80
WDC
-0.63%
101.82
NOW
-1.55%
1,383.29
SNDK
+3.77%
100.51
EPAM
+0.10%

FAQ

What Is the Certara (CERT) Stock Price Today?

The Certara stock price today is 4.59 USD.

What Stock Exchange Does Certara Trade On?

Certara is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Certara?

The stock symbol for Certara is "CERT."

What Is the Certara (CERT) Afterhours Price Today? (Afterhours variable test: 4.75) Current Date: May 19, 2026

After hours price: 4.75. After hours price change (units): 0.16. Price change percentage: 3.49%

What Is the Certara Market Cap?

As of today, Certara market cap is 718.71M USD.

What Is Certara's Earnings Per Share (TTM)?

The Certara EPS (TTM) is -0.10.

When Is the Next Certara Earnings Date?

Certara will release its next earnings report on Aug 11, 2026.

From a Technical Analysis Perspective, Is CERT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Certara Stock Split?

Certara has split 0 times.

How Many Employees Does Certara Have?

Certara has 1546 employees.

What is the current trading status of Certara (CERT)?

As of May 19, 2026, Certara (CERT) is trading at a price of 4.59 USD, with a previous close of 4.56 USD. The stock has fluctuated within a day range of 4.54 USD to 4.70 USD, while its 52-week range spans from 4.45 USD to 13.88 USD.

What Is Certara (CERT) Price Target According to Analysts?

The average 12-month price target for Certara is 7.62 USD, with a high estimate of 10 USD and a low estimate of 6 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +65.97% Upside potential.

What Is the CERT Premarket Price?

CERT's last pre-market stock price is 4.60 USD. The pre-market share volume is 280.00, and the stock has decreased by 0.04, or 0.88%.

What Is the CERT After Hours Price?

CERT's last after hours stock price is 4.75 USD, the stock has decreased by 0.16, or 3.49%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.